PTGX - Protagonist Therapeutics, Inc

91.3
-2.940   -3.220%

Share volume: 529,413
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$94.24
-2.94
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 9%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.85%
1 Month
9.60%
3 Months
4.55%
6 Months
53.19%
1 Year
136.16%
2 Year
188.47%
Key data
Stock price
$91.30
P/E Ratio 
0.00
DAY RANGE
$90.02 - $93.51
EPS 
-$2.05
52 WEEK RANGE
$37.92 - $96.54
52 WEEK CHANGE
$137.45
MARKET CAP 
5.460 B
YIELD 
N/A
SHARES OUTSTANDING 
63.809 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$682,919
AVERAGE 30 VOLUME 
$616,365
Company detail
CEO: Dinesh V. Patel
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

Recent news